SLX1B

Across TCGA pan-cancer cohorts, SLX1B RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of SLX1B’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where SLX1B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLX1B is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

LIHC, KIRC, and LUAD are the cancer types where SLX1B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLX1B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	All	All	+0.034	<.001	7	view →
KIRC	All	All	+0.017	.002	7	view →
LUAD	All	All	+0.047	<.001	6	view →
LUSC	Male	All	+0.096	<.001	5	view →
BLCA	All	All	+0.073	.003	5	view →
COAD	Female	IV	+0.180	.036	2	view →
CHOL	All	All	+0.178	.010	2	view →
STAD	All	All	+0.066	.019	2	view →
HNSC	Male	All	+0.021	.024	2	view →
THCA	Male	All	−0.034	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

SLX1B–LIHC

Open the LIHC breakdown →